Novel Agent Active in Refractory Polycythemia Vera

Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This video highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, John O. Mascarenhas, MD, of the Tisch Cancer Institute at Mount Sinai in New York, highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.

      Mascarenhas presented results of the study (abstract 254) at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.

      Recent Videos
      Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
      Spreading Greater CAR T-Cell Therapy Education in the Community Setting
      Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
      Avoiding CAR T-Cell Collection Problems Following Bridging Therapies
      Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
      Academic/Community Collaboration May Help Facilitate CAR T Therapy Access
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Hybrid Model of CAR T-Cell Therapy May Help Manage Treatment-Related Infections
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Secondary Malignancies Risk Still in Question Following CAR T-cell Therapy for Lymphoma
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Study Aims to Address CAR T Accessibility Among Disadvantaged Groups
      Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
      Addressing Challenges in TP53-Mutant Acute Myeloid Leukemia
      Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
      Menin Inhibitor Developments Move Acute Myeloid Leukemia Landscape Forward
      Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
      Advocate Outlines Resources for Chronic Myeloid Leukemia Population
      Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
      Expert Highlights Risk Factors for Disease Progression in Polycythemia Vera
      Related Content
      Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings

      Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings

      American Society for Transplantation and Cellular Therapy
      June 2nd 2025
      Article

      Researchers demonstrated that haplo-HSCT, combined with post-transplant cyclophosphamide, is a feasible and effective treatment for hematologic malignancies even in resource-limited settings.

      Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

      Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

      Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
      May 5th 2025
      Podcast

      Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

      Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

      Rusfertide Combo Enhances Responses in Polycythemia Vera

      Sabrina Serani
      June 2nd 2025
      Article

      Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

      A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

      Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

      Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
      October 21st 2024
      Podcast

      A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

      FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

      FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

      Tim Cortese
      May 6th 2025
      Article

      The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.

      Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

      FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

      Roman Fabbricatore
      April 25th 2025
      Article

      Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.